Astex Pharmaceuticals to Announce 2011 Third Quarter Financial Results on October 31, 2011

DUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery, development and commercialization of novel cancer therapies, announced that it will release its 2011 third quarter financial results on Monday, October 31, 2011. James S.J. Manuso, Ph.D., chairman and chief executive officer, and the Astex Pharmaceuticals management team, will provide details of the Company's financial results and revised outlook for the future.

A press release will be issued following the close of the market on October 31st. The Company will host a webcast conference call to discuss the results at 4:30 p.m. ET. A live webcast of the call will be available in the Investor Events section of the Company's website at www.astx.com. A webcast replay of the conference call will be available shortly following the event. Alternatively, you may access a replay of the conference call by dialing (855) 859-2056 (domestic) and (404) 537-3406 (international); replay passcode number is 21935461. The webcast replay will be available for 30 days, and the telephone replay will be available for 7 days.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. The Company is developing a proprietary pipeline of novel cancer therapeutics, will selectively in-license assets possessing a strategic fit with an attractive cost – value ratio, and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals, formerly SuperGen, developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.